Report overview
The polyvalent streptococcus pneumoniae vaccine is a vaccine that mainly prevents pneumonia caused by Streptococcus pneumoniae. It contains a variety of serotypes that often cause streptococcus pneumoniae infection. After vaccination, it can effectively reduce the risk of pneumonia infection.
This report contains market size and forecasts of Polyvalent Streptococcus Pneumococcal Vaccines in global, including the following market information:
Global Polyvalent Streptococcus Pneumococcal Vaccines Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Polyvalent Streptococcus Pneumococcal Vaccines Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Polyvalent Streptococcus Pneumococcal Vaccines companies in 2021 (%)
The global Polyvalent Streptococcus Pneumococcal Vaccines market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
9-Valent Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Polyvalent Streptococcus Pneumococcal Vaccines include GlaxoSmithKline, LG Chem, Merck, Panacea Biotec, AstraZeneca, Pfizer, Shire, Pnuvax Incorporated and Serum Institute, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Polyvalent Streptococcus Pneumococcal Vaccines manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Polyvalent Streptococcus Pneumococcal Vaccines Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Polyvalent Streptococcus Pneumococcal Vaccines Market Segment Percentages, by Type, 2021 (%)
9-Valent
13-Valent
23-Valent
Others
Global Polyvalent Streptococcus Pneumococcal Vaccines Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Polyvalent Streptococcus Pneumococcal Vaccines Market Segment Percentages, by Application, 2021 (%)
Hospital
Community Clinics
Public Health Agencies
Others
Global Polyvalent Streptococcus Pneumococcal Vaccines Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Polyvalent Streptococcus Pneumococcal Vaccines Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Polyvalent Streptococcus Pneumococcal Vaccines revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Polyvalent Streptococcus Pneumococcal Vaccines revenues share in global market, 2021 (%)
Key companies Polyvalent Streptococcus Pneumococcal Vaccines sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Polyvalent Streptococcus Pneumococcal Vaccines sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
GlaxoSmithKline
LG Chem
Merck
Panacea Biotec
AstraZeneca
Pfizer
Shire
Pnuvax Incorporated
Serum Institute
Shinogi
Shenzhen Kangtai Biological Products
SK Bioscience
Walvax Biotechnology
Eli Lilly
Abera
Sanofi
Genentech
